Fig. 5: Qualitative and neutralizing antibody studies in vaccine breakthrough patients. | Nature Microbiology

Fig. 5: Qualitative and neutralizing antibody studies in vaccine breakthrough patients.

From: Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California

Fig. 5

Graphical timeline showing results of qualitative spike and nucleoprotein antibody testing and quantitative neutralizing antibody testing against 5 variants (Alpha, Gamma, Delta and Epsilon) and a ‘non-VOC/VOI’ D614G-carrying control strain at various timepoints relative to the date of positive SARS-CoV-2 testing (t = 0) for 5 patients with vaccine breakthrough infections (P1–P5). Immunocompromised patients (P1, P2, P3 and P5) are highlighted in red text. Qualitative antibody results are shown in peach-coloured boxes, while IC50 (50% inhibitory dose) neutralizing antibody titres against the 5 variants and D614 control virus are plotted as a bar graph on a log scale. The black zigzag marks a break in the timeline.

Back to article page